Clincosm LogoSign in Get a demo

PAZOPANIB-AML: Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible

Sponsor
University Hospital Muenster (Other)
Overall Status
Completed
CT.gov ID
NCT01361334
Collaborator
Novartis (Industry)
20
Enrollment
1
Location
1
Arm
57
Duration (Months)
0.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Long term disease-free survival (DFS) of patients with acute myeloid leukemia (AML) is still poor. Recently, so-called "targeted therapy" for cancer has been introduced to the treatment of patients with AML. This phase II clinical trial will explore the efficacy, safety, and pharmacodynamics of the tyrosine kinase inhibitor pazopanib in patients with relapsed or refractory AML or patients with AML who are not eligible for intensive treatment. Biomarker studies will be included to study whether the targets are indeed inhibited and whether this leads to decreased BM angiogenesis. Toxicity assessments will be included, and the antileukemic effectiveness will be studied.

Condition or Disease Intervention/Treatment Phase
Phase 2

Study Design

Study Type:
Interventional
Actual Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Phase II Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible
Study Start Date :
Jun 1, 2011
Actual Primary Completion Date :
Mar 1, 2016
Actual Study Completion Date :
Mar 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: Pazopanib

Pazopanib treatment

Drug: Pazopanib
800 mg QD p.o.
Other Names:
  • Votrient(R)

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Cumulative response rate (CR, CRp, CRi, PR) within up to one year of pazopanib treatment [12 months]

    2. Reduction of BM microvessel density on day 28 [28 days]

    Secondary Outcome Measures

    1. Safety and Tolerability (Rate of adverse events) [12 months]

      Rate of adverse events

    2. Cumulative incidence and degree of inhibition of target receptor phosphorylation (PDGFR, VEGFR, and c-KIT) and correlation with clinical response [12 months]

    3. Reduction of BM microvessel density on day 14 [14 days]

    4. Relapse-free survival in relationship to historical control patients, Overall survival in relationship to historical control patients, Duration of response [12 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    1. Subjects must provide written informed consent prior to performance of study-specific procedures or assessments which are not routinely performed for diagnosis or monitoring of acute myeloid leukemia (AML), and the subjects must be willing to comply with treatment and to follow up assessments and procedures

    2. Histologically or cytologically confirmed diagnosis of AML relapsed after or refractory to at least one induction regimen, or patients with AML at initial diagnosis who are not eligible for allogeneic transplant or intensive induction chemotherapy, except for AML M3 (acute promyelocytic leukemia)

    3. Age at least 18 years

    4. Eastern Cooperative Oncology Group (ECOG) performance status of ≤3

    5. Measurable disease burden (blasts in BM and/or PB, extramedullary blasts [chloroma])

    6. Able to swallow and retain oral medication

    7. A life expectancy of at least 4 weeks

    8. Adequate contraception methods

    9. Adequate organ function as defined in the study protocol

    Exclusion Criteria:

    1. Patients with a valid option for intensive chemotherapy and/or stem cell transplantation (Patients after allogeneic stem cell transplant must be off immunosuppressive agents for at least 2 weeks prior to study entry and Graft-versus host disease must have resolved to Grade ≤2)

    2. History of cancer that according to the Investigator might confound the assessment of the endpoints of the study

    3. Uncontrolled peptic ulcer disease or clinically significant gastrointestinal abnormalities which interfere with oral dosing or any unstable or serious concurrent condition (e.g., active uncontrolled infection)

    4. Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥140 mmHg or diastolic blood pressure (DBP) of ≥90 mmHg]. Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. BP must be re-assessed on two occasions that are separated by a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP / DBP values from each BP assessment must be <140/90 mmHg in order for a subject to be eligible for the study

    5. Prolongation of corrected QT interval (QTc) >480 milliseconds

    6. History of any one of more of the following cardiovascular conditions within the past 6 months: cardiac angioplasty or stenting, myocardial infarction, unstable angina, symptomatic peripheral vascular disease, class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA)

    7. History of cerebrovascular infarction or bleeding, pulmonary embolism, or untreated deep venous thrombosis (DVT) within the past 6 months. Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulant agents for at least 6 weeks are eligible

    8. Evidence of serious active bleeding or bleeding diathesis (except for bleeding or petechiae due to AML-related thrombocytopenia which will be treated using platelet transfusions). Also, patients with known endobronchial lesions and/or lesions infiltrating major pulmonary vessels will be excluded from the study due to excess risk of bleeding.

    9. Prior major surgery or trauma within 28 days prior to first dose of study drug

    10. Treatment with an investigational agent within 28 days or 5 half-lives, whichever is longer prior to the first dose of study drug (for bevacizumab 60 days).

    11. Concurrent cytoreductive chemotherapy (hydroxyurea must be discontinued at least one day before start of study medication)

    12. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to pazopanib

    13. Patients with psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol

    14. Pregnant or lactating and actively breastfeeding patients

    15. Patients taking any of the following prohibited medication:

    • clarithromycin, telithromycin, troleandomycin (antibiotics)

    • ritonavir, indinavir, saquinavir, nelfinavir, amprenavir, lopinavir (HIV protease inhibitors)

    • itraconazole, ketoconazole, voriconazole, fluconazole (antifungals)

    • nefazodone (antidepressant)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Unviersity Hospital of Münster (UKM) Münster Germany 48149

    Sponsors and Collaborators

    • University Hospital Muenster
    • Novartis

    Investigators

    • Principal Investigator: Torsten Kessler, MD, University of Münster, Department of Medicine A, Germany

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital Muenster
    ClinicalTrials.gov Identifier:
    NCT01361334
    Other Study ID Numbers:
    • UKM09_0018_PAZOPANIB_AML 2011
    • 2010-024526-37
    First Posted:
    May 26, 2011
    Last Update Posted:
    Apr 8, 2021
    Last Verified:
    May 1, 2016
    Keywords provided by University Hospital Muenster
    (other than AML M3)
    Additional relevant MeSH terms:
    Leukemia
    Leukemia, Myeloid
    Leukemia, Myeloid, Acute

    Study Results

    No Results Posted as of Apr 8, 2021